An investigation for investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares over potential securities laws violations by ACADIA Pharmaceuticals Inc. was announced and NASDAQ: ACAD stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 04/25/2018 -- An investigation was announced on behalf of investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares over potential securities laws violations by ACADIA Pharmaceuticals and certain of its directors and officers.
Investors who purchased shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by ACADIA Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On April 9, 2018, it was reported that Nuplazid, Acadia's Parkinson's disease psychosis treatment, has been associated with more than 700 deaths, and that adverse event reports concerning the drug link it to additional life-threatening incidents, falls, insomnia, nausea, and fatigue. Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) declined to $15.74 per share on April 9, 2018.
Those who purchased shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com